DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Motavizumab
Motavizumab
Pdf
Phage Display-Based Strategies for Cloning and Optimization of Monoclonal Antibodies Directed Against Human Pathogens
Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: a Free Assay Disguised As Total
Structural Basis for Nonneutralizing Antibody Competition at Antigenic
Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: a Noninferiority Trial
(INN) for Biological and Biotechnological Substances
List Item Synagis-H-C-257-P46-0036 : EPAR
Michigan Care Improvement Registry HL7 2.5.1 Specification Guide for Query by Parameter (QBP)
Pediatric Pharmacy Practice Making a Difference When and Where It Counts!
(INN) for Biological and Biotechnological Substances
(RSV F) to Elicit High Neutralizing Antibody Titers
Preferred Product Characteristics of Monoclonal Antibodies for Passive
2006 Drug Trend Report
Cvx List.Pdf
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1- Exposed Infants
Wo 2009/055030 A2
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Top View
© Copyright 2018 Dennis Ryan Goulet
A Randomized Controlled Trial of Motavizumab Versus Palivizumab
Who Drug Information
Structure Basis of Neutralization by a Novel Site II/IV Antibody Against Respiratory Syncytial Virus Fusion Protein
Supplementary Tables and Figures Section 1. Distribution of CDR-H3
Combination AZD7442 Rapidly Advances Into Ph
Does Respiratory Syncytial Virus Lower Respiratory Illness in Early Life Cause
Drug Monographs
Astrazeneca Scales Back Motavizumab
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
Gold Standard Drug Monographs
Therapeutic Neutralizing Monoclonal Antibodies: Report of a Summit Sponsored by Operation Warp Speed and the National Institutes of Health
The South East London Red, Amber, Grey (RAG) Medicines List for Adults - Updated January 2020
Clinicalkey Drug Monographs
(12) Patent Application Publication (10) Pub. No.: US 2015/0293.086 A1 MESSMER Et Al
(INN) for Biological and Biotechnological Substances
Passive Immunoprophylaxis Against Respiratory Syncytial Virus in Children: Where Are We Now?
Standouts Melanoma Drug Yervoy, with Seemingly Better Tolerability
Concept ID Name Class 1319998 Acebutolol Adrenergics 1154343
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
An Epitope-Specific Chemically Defined Nanoparticle Vaccine For
Development of Antibody Therapeutics Against Flaviviruses
Prevention of Serious Respiratory Syncytial Virus-Related Illness. II: Immunoprophylaxis